Argenx Se (ARGX) Non-Current Deferred Tax Liability (2020 - 2024)
Argenx Se's (ARGX) quarterly Non-Current Deferred Tax Liability came in at $5.0 million in Q2 2024, down 43.85% YoY from $8.9 million in Q3 2023, and down 3.12% on a QoQ basis from $5.2 million in Q4 2023.
Argenx Se (ARGX) Non-Current Deferred Tax Liability (2020 - 2024) Analysis & Trends
Argenx Se (ARGX) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $5.0 million in Q2 2024.
- Quarterly Non-Current Deferred Tax Liability fell 43.85% year-over-year to $5.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $5.0 million (down 43.85% YoY) and the FY2023 annual result came in at $5.2 million, down 38.67% from the prior year.
- Non-Current Deferred Tax Liability eased to $5.0 million in Q2 2024, from $5.2 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $12.4 million in Q2 2021 to a low of $959371.8 in Q2 2020.
- A 5-year average of $6.3 million and a median of $6.4 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability soared 1191.26% — and 2024, when it sank 43.85%.
- Tracing ARGX's Non-Current Deferred Tax Liability over 5 years: stood at $1.4 million in 2020, then jumped by 345.52% to $6.4 million in 2021, then jumped by 30.57% to $8.4 million in 2022, then slumped by 38.67% to $5.2 million in 2023, then slipped by 3.12% to $5.0 million in 2024.
- The last three Non-Current Deferred Tax Liability figures came in at $5.0 million (Q2 2024), $5.2 million (Q4 2023), and $8.9 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 4.99 Mn |
| Jun 30, 2024 | 4.99 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Jun 30, 2023 | 8.89 Mn |
| Jun 30, 2023 | 8.89 Mn |
| Dec 31, 2022 | 8.41 Mn |
| Dec 31, 2022 | 8.41 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Dec 31, 2021 | 6.44 Mn |
| Dec 31, 2021 | 6.44 Mn |
| Jun 30, 2021 | 12.39 Mn |
| Jun 30, 2021 | 12.39 Mn |
| Dec 31, 2020 | 1.45 Mn |
| Dec 31, 2020 | 1.45 Mn |
| Jun 30, 2020 | 959,371.77 |
| Jun 30, 2020 | 959,371.77 |